Management of hyperbilirubinaemia in pancreatic cancer patients

Eur J Cancer. 2018 May;94:26-36. doi: 10.1016/j.ejca.2018.01.078. Epub 2018 Mar 20.

Abstract

Development of hyperbilirubinaemia is common in patients with advanced pancreatic adenocarcinoma, both at diagnosis as well throughout disease evolution. For this reason, hyperbilirubinaemia determines chemotherapy treatment selection, and therefore it should be considered one of the most relevant conditions. There is very little evidence for the use of chemotherapy in this setting. This article summarises the main causes of hyperbilirubinaemia, how to treat them as well as their differential diagnosis. The current clinical evidence of the available drugs as well as the recommendations of use different combinations in the context of hyperbilirubinaemia are also reviewed.

Keywords: Hyperbilirubinemia; Management; Pancreatic adenocarcinoma.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Carcinoma, Pancreatic Ductal / complications*
  • Humans
  • Hyperbilirubinemia / diagnosis
  • Hyperbilirubinemia / etiology*
  • Hyperbilirubinemia / therapy*
  • Pancreatic Neoplasms / complications*